Market closed
Veru/$VERU
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Veru
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Ticker
$VERU
Sector
Trading on
Industry
Personal Care Products
Headquarters
Employees
210
Website
Veru Metrics
BasicAdvanced
$93M
-
-$0.28
-0.55
-
Price and volume
Market cap
$93M
Beta
-0.55
52-week high
$1.92
52-week low
$0.36
Average daily volume
3.9M
Financial strength
Current ratio
2.968
Quick ratio
2.433
Long term debt to equity
36.428
Total debt to equity
42.899
Interest coverage (TTM)
-62.78%
Management effectiveness
Return on assets (TTM)
-43.17%
Return on equity (TTM)
-145.40%
Valuation
Price to revenue (TTM)
5.073
Price to book
2.88
Price to tangible book (TTM)
3.65
Price to free cash flow (TTM)
-3.922
Growth
Revenue change (TTM)
3.62%
Earnings per share change (TTM)
-74.43%
3-year revenue growth (CAGR)
-34.92%
3-year earnings per share growth (CAGR)
46.03%
What the Analysts think about Veru
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Veru stock.
Veru Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Veru Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Veru News
AllArticlesVideos
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
GlobeNewsWire·2 days ago
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
GlobeNewsWire·4 weeks ago
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Veru stock?
Veru (VERU) has a market cap of $93M as of January 29, 2025.
What is the P/E ratio for Veru stock?
The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of January 29, 2025.
Does Veru stock pay dividends?
No, Veru (VERU) stock does not pay dividends to its shareholders as of January 29, 2025.
When is the next Veru dividend payment date?
Veru (VERU) stock does not pay dividends to its shareholders.
What is the beta indicator for Veru?
Veru (VERU) has a beta rating of -0.55. This means that it has an inverse relation to market volatility.